Professional healthcare presentation on expanding community access to bispecific therapies with Dr. Loretta Nastoupil and Dr. Raji Shameem.

Videos & Podcasts

09/10/2026

Part 2: How to Expand Community Access to Bispecific Therapies

Loretta Nastoupil, MDRaji Shameem, MD

Raji Shameem, MD, and Loretta Nastoupil, MD, discuss the value of connecting satellite clinics with academic centers and experienced community sites through standardized procedures, virtual tumor boards, and shared best practices to support bispecific antibody therapy.

Panel of five medical experts discussing ongoing myelofibrosis trials and future treatment paradigms at OncUpdates.

Clinical Insights

09/09/2026

Ep. 4: Ongoing Trials and Future Treatment Paradigms for Myelofibrosis

Three doctors, Dr. Aaron Gerds, Dr. Rohit Gosain, and Dr. Rahul Gosain, discussing treatment updates for polycythemia vera and essential thrombocythemia.

Videos & Podcasts

09/09/2026

The Rapidly Shifting Treatment Algorithms for Polycythemia Vera and Essential Thrombocythemia

Group photo of four medical professionals including Dr. Joshua Brody, Dr. Sarah Rutherford, Dr. Rohit Gosain, and Dr. Rahul Gosain, discussing managing side effects of bispecific antibodies for B-cell.

Clinical Insights

09/08/2026

Ep. 2: Managing Adverse Effects of Bispecific Antibodies for B-Cell Lymphoma

Panel of four breast cancer experts discussing ctDNA use in real-world practice for breast cancer management.

Clinical Insights

09/04/2026

Ep. 3: How Breast Cancer Experts Use ctDNA in Real-World Practice

Conferences

View All
Panel of three medical professionals at EHA 2026 conference discussing leukemia and myelofibrosis presentations.

Conferences

08/03/2026

Key Leukemia and Myelofibrosis Presentations at EHA 2026

Eunice Wang, MDRahul Gosain, MD, MBARohit Gosain, MD
Group photo of three medical professionals discussing lymphoma presentations at EHA 2026.

Conferences

07/31/2026

4 Key Lymphoma Presentations From EHA 2026

Carla Casulo, MDRahul Gosain, MD, MBARohit Gosain, MD
Two doctors, Dr. Rahul Banerjee and Dr. Rohit Gosain, featured in a digital graphic about emerging data for CELMoDs in multiple myeloma.

Conferences

07/22/2026

The Emerging Data for CELMoDs in Multiple Myeloma

Rahul Banerjee, MD, FACPRohit Gosain, MD
Experts Dr. Rahul Gosain, Dr. Rohit Gosain, Dr. Brian Rini, and Dr. Thomas Powles discuss 6 clinical trials on treatment options for genitourinary cancers.

Conferences

07/15/2026

6 Trials Impacting Treatment Options for Genitourinary Cancers

Thomas Powles, MD, MBBS, MRCPBrian Rini, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD
Group of three medical professionals, including Dr. Hope Rugo, discussing breast cancer updates from ASCO 2026.

Conferences

07/13/2026

7 Key Breast Cancer Updates From ASCO 2026

Hope Rugo, MD, FASCORahul Gosain, MD, MBARohit Gosain, MD
Dr. Rahul Banerjee, Dr. Rohit Gosain, and Dr. Rahul Gosain discuss key updates from EHA 2026 on multiple myeloma trials.

Conferences

07/07/2026

5 Key Multiple Myeloma Trial Updates From EHA 2026

Rohit Gosain, MDRahul Gosain, MD, MBARahul Banerjee, MD, FACP
Dr. Neena Vijayvergia, Dr. Rahul Gosain, and Dr. Rohit Gosain discussing key gastrointestinal trials at ASCO 2026 for clinical practice.

Conferences

07/02/2026

ASCO 2026: Key GI Trials Shaping Clinical Practice

Neena Vijayvergia, MDRahul Gosain, MD, MBARohit Gosain, MD
Dr. Joshua Brody, MD, in front of New York City skyline, discussing Liso-Cel treatment for relapsed DLBCL patients.

Conferences

07/02/2026

Liso-Cel in Relapsed DLBCL: Patient Selection, Outcomes, and Referral Strategies

Joshua Brody, MD

Clinical Insights

View All
Panel of five medical experts discussing ongoing myelofibrosis trials and future treatment paradigms at OncUpdates.

Clinical Insights

09/09/2026

Ep. 4: Ongoing Trials and Future Treatment Paradigms for Myelofibrosis

Nikolai Podoltsev, MD, PhDRaajit Rampal, MD, PhDSrinivas Tantravahi, MBBS, MRCPPankit Vachhani, MDRahul Gosain, MD, MBARohit Gosain, MD
Group photo of four medical professionals including Dr. Joshua Brody, Dr. Sarah Rutherford, Dr. Rohit Gosain, and Dr. Rahul Gosain, discussing managing side effects of bispecific antibodies for B-cell.

Clinical Insights

09/08/2026

Ep. 2: Managing Adverse Effects of Bispecific Antibodies for B-Cell Lymphoma

Joshua Brody, MDSarah Rutherford, MDRahul Gosain, MD, MBARohit Gosain, MD
Panel of four breast cancer experts discussing ctDNA use in real-world practice for breast cancer management.

Clinical Insights

09/04/2026

Ep. 3: How Breast Cancer Experts Use ctDNA in Real-World Practice

Matthew Kurian, MDWassim McHayleh, MDEleonora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD
Group photo of four medical professionals discussing B-cell lymphomas for OncUpdates.

Clinical Insights

09/02/2026

Ep. 1: Bispecific Antibody Options for Relapsed or Refractory B-Cell Lymphomas 

Joshua Brody, MDSarah Rutherford, MDRahul Gosain, MD, MBARohit Gosain, MD
Panel discussion on incorporating the SENTRY regimen and managing side effects with five medical experts including Dr. Nikolai Podoltsev and Dr. Pankit Vachhani.

Clinical Insights

09/02/2026

Ep. 3: Incorporating the SENTRY Regimen and Managing Side Effects in Myelofibrosis

Nikolai Podoltsev, MD, PhDRaajit Rampal, MD, PhDSrinivas Tantravahi, MBBS, MRCPPankit Vachhani, MDRahul Gosain, MD, MBARohit Gosain, MD
Panel discussing current challenges of ctDNA testing in breast cancer with expert doctors.

Clinical Insights

08/28/2026

Ep. 2: Challenges of ctDNA Testing in Breast Cancer

Matthew Kurian, MDWassim McHayleh, MDEleonora Teplinsky, MDRahul Gosain, MD, MBARohit Gosain, MD
Panel of five medical researchers discussing SENTRY trial involving Selinexor and Ruxolitinib for myelofibrosis treatment.

Clinical Insights

08/26/2026

Ep. 2: Phase 3 SENTRY Trial: Selinexor Plus Ruxolitinib in Myelofibrosis

Nikolai Podoltsev, MD, PhDRaajit Rampal, MD, PhDSrinivas Tantravahi, MBBS, MRCPPankit Vachhani, MDRahul Gosain, MD, MBARohit Gosain, MD
Team of medical researchers discussing bispecific antibody therapy for B-cell lymphoma at OncUpdates.

Clinical Insights

08/22/2026

Making a Case for Bispecific Antibody Therapy in B-Cell Lymphoma

Joshua Brody, MDSarah Rutherford, MDRahul Gosain, MD, MBARohit Gosain, MD

Treatment Algorithms

View All
Three doctors, Dr. Aaron Gerds, Dr. Rohit Gosain, and Dr. Rahul Gosain, discussing treatment updates for polycythemia vera and essential thrombocythemia.

Treatment Algorithm

09/09/2026

The Rapidly Shifting Treatment Algorithms for Polycythemia Vera and Essential Thrombocythemia

Aaron Gerds, MDRahul Gosain, MD, MBARohit Gosain, MD
Group photo of three doctors, including Dr. Thomas LeBlanc, Dr. Rohit Gosain, and Dr. Rahul Gosain, discussing treatment options for lower-risk myelodysplastic syndrome.

Treatment Algorithm

08/17/2026

Critical Role of Luspatercept in the Treatment of Lower-Risk Myelodysplastic Syndrome

Thomas LeBlanc, MD, MARahul Gosain, MD, MBARohit Gosain, MD
Three medical professionals discussing treatment options for late relapsed multiple myeloma, featuring Dr. Maximilian Merz, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Treatment Algorithm

08/06/2026

Treatment Options and Sequencing for Late Relapsed/Refractory Multiple Myeloma

Maximilian Merz, MDRahul Gosain, MD, MBARohit Gosain, MD
Promotional image for OncUpdates featuring Dr. Shaji Kumar, Dr. Rohit Gosain, and Dr. Rahul Gosain discussing navigating first relapse in multiple myeloma.

Treatment Algorithm

08/06/2026

Navigating First Relapse in Multiple Myeloma

Shaji Kumar, MDRahul Gosain, MD, MBARohit Gosain, MD
Group of three medical professionals discussing guidelines for systemic therapy during radiation therapy.

Treatment Algorithm

08/02/2026

Guidelines for Continuing or Holding Systemic Therapy During Radiation Therapy

Nina Sanford, MDRahul Gosain, MD, MBARohit Gosain, MD
Three medical professionals, including Dr. Gurbakhash Kaur, Dr. Rohit Gosain, and Dr. Rahul Gosain, discussing treatment algorithms for newly diagnosed and smoldering multiple myeloma in 2026.

Treatment Algorithm

07/29/2026

2026 Treatment Algorithms for Newly Diagnosed and Smoldering Multiple Myeloma

Gurbakhash Kaur, MDRahul Gosain, MD, MBARohit Gosain, MD
Medical professionals discussing treatment options for BRAF V600E-mutated NSCLC, highlighting personalized approaches and targeted therapies for lung cancer patients.

Treatment Algorithm

05/26/2026

How To Select Between Treatment Options for BRAF V600E–Mutated NSCLC

Gregory Riely, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD
Advanced frontline therapy for metastatic NSCLC without actionable mutations.

Treatment Algorithm

05/18/2026

The Frontline Treatment Algorithm for Metastatic NSCLC Without Actionable Mutations

Chirstine Garcia, MD, MPHRahul Gosain, MD, MBARohit Gosain, MD

Challenging Cases

View All
Medical professionals discussing treatment options for myelodysplastic syndromes in a clinical setting.

Challenging cases

08/18/2026

Navigating Frontline Treatment and Disease Progression in Myelodysplastic Syndromes

Amer Zeidan, MBBS, MDRahul Gosain, MD, MBARohit Gosain, MD
Medical conference image featuring Dr. Matthew Lunning, Dr. Gilles Salles, Dr. Rohit Gosain, and Dr. Rahul Gosain discussing challenging DLBCL cases.

Challenging cases

07/30/2026

Challenging DLBCL Cases: Early Relapse and Follicular Lymphoma Transformation

Matthew Lunning, DO, FACPGilles Salles, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD
Panel discussion on treatment options in multiple myeloma featuring Dr. Marco Davila, Dr. Krina Patel, Dr. Rohit Gosain, and Dr. Rahul Gosain at OncUpdates.

Challenging cases

07/27/2026

Myeloma Specialists Discuss Treatment Options in Multiple Myeloma Cases

Marco Davila, MD, PhDKrina Patel, MD, MScRahul Gosain, MD, MBARohit Gosain, MD
Three doctors, including Dr. Pedro Barata, Dr. Rohit Gosain, and Dr. Rahul Gosain, are featured in a professional medical setting with a red background, discussing metastatic RCC treatment options.

Challenging cases

07/03/2026

Selecting Frontline and Subsequent Treatment Options for Metastatic RCC

Pedro Barata, MD, MSc, FACPRahul Gosain, MD, MBARohit Gosain, MD
Prominent oncology experts Dr. Shirish Gadgeel, Dr. Wade Iams, Dr. Rohit Gosain, and Dr. Rahul Gosain discuss advanced treatment and management options for mEGFR NSCLC patients.

Challenging cases

06/04/2026

Experts Review Best Practices in Metastatic EGFR–Mutated NSCLC Cases

Shirish Gadgeel, MBBS, FASCOWade Iams, MD, MSCIRahul Gosain, MD, MBARohit Gosain, MD
Experts evaluate targeted therapies for relapsed or refractory AML in challenging cases, featuring Dr. Joshua Zeidner, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Challenging cases

05/27/2026

Experts Evaluate Targeted Therapies in Relapsed or Refractory AML

Joshua Zeidner, MDRahul Gosain, MD, MBARohit Gosain, MD
Dr. Fadi Haddad, Dr. Gabriela Hobbs, Dr. Rohit Gosain, and Dr. Rahul Gosain discuss challenging oncology cases, including frontline TKI for CML and treatment options.

Challenging cases

05/25/2026

Challenging Cases: Frontline TKI for CML and Options Upon Progression

Fadi Haddad, MDGabriela Hobbs, MDRahul Gosain, MD, MBARohit Gosain, MD
Advanced medical professionals discussing evolving treatment options for therapy-related and de novo AML in hematology research.

Challenging cases

02/11/2026

Challenging Cases: The Evolving Treatment Landscape for Therapy-Related and De Novo AML

Naval Daver, MDRahul Gosain, MD, MBARohit Gosain, MD

New Approvals

View All
Dr. Andrew Kuykendall, Dr. Rahul Gosain, and Dr. Rohit Gosain discuss the VERIFY trial and FDA approval of Rusfertide for PV in a professional medical presentation.

New Approvals

08/29/2026

Discussing the VERIFY Trial and the FDA Approval of Rusfertide for PV

Andrew Kuykendall, MDRahul Gosain, MD, MBARohit Gosain, MD
OncUpdates article on Zanidatamab combinations approved for HER2+ gastroesophageal cancers featuring Dr. Natalya Uboha, Dr. Rahul Gosain, and Dr. Rohit Gosain.

New Approvals

08/27/2026

Zanidatamab Combinations Approved for HER2+ Gastroesophageal Cancers

Nataliya Uboha, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD
OncUpdates article featuring Dr. Sagar Lonial, Dr. Rahul Gosain, and Dr. Rohit Gosain discussing treatment options for relapsed or refractory multiple myeloma.

New Approvals

08/26/2026

Iberdomide Expands Treatment Options in Relapsed or Refractory Multiple Myeloma

Sagar Lonial, MD, FACP, FASCORahul Gosain, MD, MBARohit Gosain, MD
Group photo of four medical professionals, including Dr. Shaji Kumar, Dr. Vincent Rajkumar, Dr. Rahul Gosain, and Dr. Rohit Gosain, discussing findings from ENDURANCE trial for multiple myeloma.

New Approvals

08/05/2026

Findings From ENDURANCE Trial Offer New Standard of Care for Multiple Myeloma

Shaji Kumar, MDS. Vincent Rajkumar, MDRahul Gosain, MD, MBARohit Gosain, MD
Dr. Sara Tolaney, Dr. Rahul Gosain, and Dr. Rohit Gosain discuss new indications for Sacituzumab Govitecan in TNBC.

New Approvals

07/13/2026

ASCENT-03 and ASCENT-04 Lead to New Indications for Sacituzumab Govitecan in TNBC

Sara Tolaney, MD, MPHRahul Gosain, MD, MBARohit Gosain, MD
Dr. Scott Kopetz discusses a new treatment option for metastatic colorectal cancer with BRAF V600E mutation, featuring experts Dr. Rahul Gosain and Dr. Rohit Gosain.

New Approvals

04/30/2026

BREAKWATER: New Treatment Option for Metastatic Colorectal Cancer With BRAF V600E Mutation

Scott Kopetz, MD, PhDRahul Gosain, MD, MBARohit Gosain, MD
Dr. Luciano Costa, Dr. Rahul Gosain, and Dr. Rohit Gosain discussing approved treatments for relapsed multiple myeloma, highlighting recent advances in oncology research.

New Approvals

03/10/2026

Teclistamab Plus Daratumumab Approved for Relapsed or Refractory Multiple Myeloma After MajesTEC-3

Luciano Costa, MDRahul Gosain, MD, MBARohit Gosain, MD
Expert panel discussing clinical implications of Enfortumab Vedotin plus Pembrolizumab in cisplatin-ineligible metastatic bladder cancer at OncUpdates.

New Approvals

03/03/2026

Transformative Data in Cisplatin-Ineligible MIBC: Clinical Implications of Enfortumab Vedotin Plus Pembrolizumab

Thomas Powles, MD, MBBS, MRCPRahul Gosain, MD, MBARohit Gosain, MD

Tox Check

View All
Team of medical experts discussing managing toxicities in prostate cancer treatment with androgen receptor pathway inhibitors.

Tox Check

08/22/2026

A Guide to Managing Toxicities Across Four Androgen Receptor Pathway Inhibitors in Prostate Cancer

Alicia Morgans, MD, MPHChristopher Pieczonka, MDRahul Gosain, MD, MBARohit Gosain, MD
Group photo of three doctors discussing CAR T-Cell Therapy in Multiple Myeloma, highlighting collaboration and adverse effects management.

Tox Check

08/04/2026

CAR T-Cell Therapy in Multiple Myeloma: Managing Adverse Effects Through Collaboration

Caitlin Costello, MDJoshua Richter, MDRahul Gosain, MD, MBARohit Gosain, MD
Group photo of three medical professionals discussing BRAF and MEK inhibitor side effects in NSCLC, featuring Dr. Melissa Johnson, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Tox Check

05/28/2026

BRAF and MEK Inhibitor Side Effects in BRAF V600E–Mutated NSCLC

Melissa Johnson, MDRahul Gosain, MD, MBARohit Gosain, MD
Experts discussing targeted therapy strategies for managing toxicities in multiple myeloma treatment, featuring Dr. Hamza Hashmi, Dr. Cesar Rodriguez, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Tox Check

05/20/2026

Bispecific Therapy in Multiple Myeloma: Strategies for Managing Toxicities

Hamza Hashmi, MDCesar Rodriguez, MDRahul Gosain, MD, MBARohit Gosain, MD
Expert discussion on managing side effects of EGFR inhibitors in non-small cell lung cancer (NSCLC) with Dr. Azam Farooqi, Dr. Joshua Sabari, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Tox Check

05/18/2026

How To Manage Side Effects of EGFR Inhibitors in NSCLC

Azam Farooqui, MDJoshua Sabari, MDRahul Gosain, MD, MBARohit Gosain, MD
Expert guidance on managing side effects of colorectal cancer therapies, featuring Dr. Rona Yaeger and colleagues, for improved patient care and treatment outcomes.

Tox Check

05/06/2026

How to Manage Side Effects of Colorectal Cancer Therapies

Rona Yaeger, MDRahul Gosain, MD, MBARohit Gosain, MD
Toxicity check for PI3K/AKT inhibitor side effects in metastatic breast cancer with experts Dr. Emily Gallagher and Dr. Neil Iyengar.

Tox Check

01/06/2026

PI3K/AKT Inhibitor Side Effect Management in Metastatic Breast Cancer

Emily Gallagher, MD, PhDNeil Iyengar, MDRohit Gosain, MDRahul Gosain, MD, MBA
Toxicity awareness in novel antibody-drug conjugates and NSCLC, featuring expert insights from Dr. Jacob Sands, Dr. Rohit Gosain, and Dr. Rahul Gosain on key adverse effects and safety considerations.

Tox Check

01/02/2026

Key Adverse Effects of Novel Antibody-Drug Conjugates in NSCLC

Jacob Sands, MDRahul Gosain, MD, MBARohit Gosain, MD

Partners in Practice

View All
Group photo of medical professionals discussing supportive care in managing multiple myeloma, featuring Ms. Samantha Shenoy, Dr. Ajai Chari, Ms. Jenny Truong, Dr. Rohit Gosain, and Dr. Rahul Gosain.

Partners in Practice

09/03/2026

The Critical Role of Supportive Care in Managing Multiple Myeloma

Ajai Chari, MDSamantha Shenoy, NPJenny Truong, RNRahul Gosain, MD, MBARohit Gosain, MD
Group photo of four medical professionals, including Dr. Timothy Brown, Dr. Heather Kline, Dr. Rohit Gosain, and Dr. Rahul Gosain, discussing pancreatic cancer management.

Partners in Practice

08/11/2026

Ongoing Dialogue: A Team-Based Approach to Pancreatic Cancer Management

Timothy Brown, MD, MSCEHeather Kline, MS, APRN, FNP-CRahul Gosain, MD, MBARohit Gosain, MD

Rapid Fire Rounds

View All
Myeloma specialist Dr. Joseph Mikhael answers community questions on CAR T-Cell Therapy, MRD, and CELMoDs, featuring Dr. Rohit Gosain and Dr. Rahul Gosain at OncUpdates.

Rapid Fire Rounds

08/31/2026

Myeloma Specialist Answers Community Questions on CAR T-Cell Therapy, MRD, and CELMoDs

Joseph Mikhael, MD, MEdRahul Gosain, MD, MBARohit Gosain, MD

Resource Centers

View All
Two doctors, Dr. Maximilian Merz and Dr. Hamza Hashmi, discuss sequencing BCMA-directed therapies for relapsed/refractory multiple myeloma at a medical conference.

Resource Centers

08/18/2026

CAR-T First Emerges as Recommended Therapy For Relapsed/Refractory Multiple Myeloma

Hamza Hashmi, MDMaximilian Merz, MD
Two doctors, Dr. Hamza Hashmi and Dr. Maximilian Merz, discussing optimizing Cilta-Cel use in relapsed/refractory multiple myeloma.

Resource Centers

08/18/2026

Earlier Line Therapy With Cilta-Cel To Treat Relapsed/Refractory Multiple Myeloma

Hamza Hashmi, MDMaximilian Merz, MD
Group photo of three doctors discussing CAR T-Cell Therapy in Multiple Myeloma, highlighting collaboration and adverse effects management.

Resource Centers

08/04/2026

CAR T-Cell Therapy in Multiple Myeloma: Managing Adverse Effects Through Collaboration

Caitlin Costello, MDJoshua Richter, MDRahul Gosain, MD, MBARohit Gosain, MD
Panel discussion on treatment options in multiple myeloma featuring Dr. Marco Davila, Dr. Krina Patel, Dr. Rohit Gosain, and Dr. Rahul Gosain at OncUpdates.

Resource Centers

07/27/2026

Myeloma Specialists Discuss Treatment Options in Multiple Myeloma Cases

Marco Davila, MD, PhDKrina Patel, MD, MScRahul Gosain, MD, MBARohit Gosain, MD
Overview of CAR T-cell therapy and bispecific antibodies for relapsed or refractory multiple myeloma with real-world sequencing insights.

Resource Centers

07/14/2026

CAR T or Bispecific Antibodies First? Real-World Sequencing Insights in Relapsed/Refractory Multiple Myeloma

Sawyer Bawek, DO
CAR T-cell therapy in multiple myeloma with insights from ASCO 2026, featuring experts Dr. Binod Dhakal, Dr. Surbhi Sidana, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Ajai Chari.

Resource Centers

06/27/2026

CAR T in Myeloma: Earlier Use and Sequencing Insights from ASCO 2026

Ajai Chari, MDBinod Dhakal, MDSurbhi Sidana, MDRahul Gosain, MD, MBARohit Gosain, MD
Two medical professionals, a woman and a man, in white coats with a city skyline background, discussing RAS-targeted therapy in pancreatic adenocarcinoma.

Resource Centers

06/19/2026

Daraxonrasib and the Future of RAS Inhibitors in Pancreatic Cancer

Antonella Cammarota, PhDMichael May, MD
Panel discussion on managing toxicity and expanding RAS therapy in pancreatic cancer featuring Dr. Andrew H. Ko, Dr. Eileen O'Reilly, Dr. Rohit Gosain, Dr. Rahul Gosain, Dr. Rachna Shroff, and Dr. Shu.

Resource Centers

06/16/2026

Managing Toxicity and Expanding RAS Therapy in Pancreatic Cancer

Andrew H. Ko, MDEileen O'Reilly, MDShubham Pant, MD, MBBSRachna Shroff, MD, MS, FASCORahul Gosain, MD, MBARohit Gosain, MD

Articles

View All
Image featuring pills with a text overlay about a new targeted pill for metastatic pancreatic cancer and FDA approval of Daraxonrasib.

Article

09/02/2026

A New Targeted Pill for Metastatic Pancreatic Cancer: What the FDA Approval of Daraxonrasib Means for Patients

Sawyer Bawek, DO
Healthcare professional in blue scrubs holding a tablet with a news headline about Rusfertide approval for PV patients.

Article

08/29/2026

Rusfertide Approval Offers Novel Treatment Approach for Patients With PV

OncUpdates
Daraxonrasib approved for metastatic pancreatic cancer treatment, shown in a laboratory setting with test tubes and a gloved hand.

Article

08/27/2026

Daraxonrasib Approved for Previously Treated Metastatic Pancreatic Cancer

OncUpdates
FDA approves Zandidatamab for HER2-positive gastroesophageal adenocarcinoma, as announced by SignifyMD in a press release.

Article

08/25/2026

FDA Approves Zanidatamab-hrii Plus Tislelizumab-jsgr for HER2-Positive Gastroesophageal Adenocarcinoma

OncUpdates
Educational infographic on two years of maintenance therapy for standard-risk multiple myeloma from the ENDURANCE trial.

Article

08/20/2026

2 Years of Maintenance May Be Enough for Some Patients With Standard-Risk Multiple Myeloma: ENDURANCE Trial Breakdown

Sawyer Bawek, DO
Laboratory technician handling test tubes with blood samples, related to FDA approval of Iberdomide for relapsed multiple myeloma treatment.

Article

08/13/2026

FDA Grants Accelerated Approval to Iberdomide Combination for Relapsed Multiple Myeloma

OncUpdates
Hematology/Oncology fellowship interview tips based on personal experience, featuring Sawyer Bawek, DO, from Cleveland Clinic Taussig Cancer Institute.

Article

08/13/2026

Hematology/Oncology Fellowship Interview Tips Based on Personal Experience

Sawyer Bawek, DO
Healthcare professional holding a tray of blood samples at ISTH 2026 conference on cancer-associated thrombosis.

Article

07/30/2026

ISTH 2026: Key Takeaways in Cancer-Associated Thrombosis and Thrombocytopenia 

William Archibald, MDKevin Zablonski, MD

Events

View Events
Advancements in Oncology: SABCS in San Antonio, TX

Advancements in Oncology: SABCS in San Antonio, TX

December 9, 2026

Join the Oncology Brothers and leading experts in San Antonio for an exclusive live event exploring how new...

Clinicals to Exam: Hematology in New Orleans, LA

Clinicals to Exam: Hematology in New Orleans, LA

December 11, 2026

Coinciding with ASH 2026 in New Orleans, this complimentary program created for hematology fellows brings board-relevant concepts to...

Advancements in Oncology: ASH in New Orleans, LA

Advancements in Oncology: ASH in New Orleans, LA

December 13, 2026

Join the Oncology Brothers and leading experts in New Orleans for an exclusive live event exploring how new...

Advancements in Oncology: ASCO GI in San Francisco, CA

Advancements in Oncology: ASCO GI in San Francisco, CA

January 21, 2027

Join the Oncology Brothers and leading experts in San Francisco for an exclusive live event exploring how new...